Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions (Details)

v2.4.0.6
Composition of Certain Financial Statement Captions (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Accounts receivable, net:    
Accounts receivable $ 19,490 $ 12,984
Less allowance for doubtful accounts (348) (440)
Accounts receivable, net 19,142 12,544
Inventories, net:    
Finished products 17,750 11,100
Work-in process 633 277
Raw materials 4,513 2,287
Less: reserve for obsolescence (1,408) (325)
Inventories, net 21,488 13,339
Intangible assets, net    
Customer relationships 19,232 18,386
In process research and development 11,504 10,000
Technology 50,211 47,100
Product registrations 9,638 3,895
Tradename 1,921 827
Covenants not to compete 1,758 1,560
Other 297 297
Less: accumulated amortization (11,975) (5,335)
Intangible assets, net 82,586 76,730
Accrued expenses    
Income taxes payable 649 484
Deferred revenue 955 530
Clinical trials 58 7
Professional fees 817 632
Employee benefits 1,910 907
Deferred acquisition payments net of discount 5,983   
Contingent consideration 7,992   
Other 3,430 2,396
Accrued expenses, net 21,794 4,956
Other long-term liabilities:    
Contingent consideration 13,909 18,002
Deferred acquisition payments net of discount 3,769   
Deferred tax liabilities 10,845 6,863
Long term debt 3,954   
Other including deferred revenue 453 578
Other long-term liabilities, principally contingent consideration and deferred tax liabilities $ 32,930 $ 25,443